Publication date: 16/11/2017
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today provides a business update for the third quarter of 2017, post-period events and an outlook for the remainder of the year.
Commenting on the business update, Herman Verrelst, Chief Executive Officer of Biocartis, said: "I am pleased to present today the first business update in my capacity as CEO. Q3 was a quarter in which Biocartis made impressive progress on all fronts. The start of commercialization in the US is a crucial next step in the commercial roll-out of our Idylla(TM) platform, and a key revenue driver in the mid-term. I look forward to work with our partner Thermo Fisher Scientific to make Idylla(TM) the go-to platform for clinical oncology molecular diagnostics (MDx) in the US. The new collaborations with Genomic Health and A*STAR further demonstrate our ability to enter into collaborations with renowned development partners. I see it as a major validation that Genomic Health has chosen our Idylla(TM) platform to increase global patient access to standard-of-care testing with the Oncotype DX Breast Recurrence Score® test. Adding additional partnerships with pharma and biotech companies, for amongst others Companion Diagnostics (CDx) development, as well as attracting additional exclusive biomarker content for our tests, will assist Biocartis in its mission to make personalized medicine an everyday reality."
Commercial and regulatory update
The Idylla(TM) breast cancer menu is the first cancer subtype menu on the Idylla(TM) platform that is to be fully developed with partners.
Organizational and operational update
Menu outlook 2017
Financial calendar 2018
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system that offers accurate, highly reliable molecular information from virtually any biological sample in virtually any setting. Biocartis launched the Idylla(TM) platform in 2014. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest growing and largest segments of the MDx market worldwide. Today, Biocartis has ten oncology tests and two infectious disease tests in its product menu. More information: www.biocartis.com. Press Photo Library available here. Follow us on Twitter: @Biocartis_.